Clinical trial of bevacizumab injection combined with neoadjuvant chemotherapy in the treatment of breast cancer
10.13699/j.cnki.1001-6821.2018.19.007
- VernacularTitle:贝伐珠单抗注射液联合新辅助化疗治疗乳腺癌的临床研究
- Author:
Qiu-Yun CHEN
1
;
Lei WANG
Author Information
1. 常州市第七人民医院 乳腺科
- Keywords:
bevacizumab injection;
neoadjuvant chemotherapy;
breast cancer;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(19):2266-2268
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of be-vacizumab injection combined with neoadjuvant chemotherapy in the treatment of breast cancer.Methods A total of 102 patients of breast cancer were randomly divided into control and treatment groups with 51 cases per group.Control group was given 5 -fluorouracil 500 mg· m-2per time, day 1, intravenous injection +cyclophosphamide 50 mg· m-2per time, day 1, 8, intravenous injection +epirubicin 50 mg· m-2, day 1, intrave-nous injection.Treatment group received 15 mg· kg -1bevacizumab per time, day 1, intravenous injection, on the basis of control group.Two groups were treated for 3 cycles with 21 days per cycle.The clinical effi-cacy, the positive expression rates of p53, Ki-67, matrix metalloprotei-nase-2 ( MMP -2 ) and MMP -9, and adverse drug reactions were compared between two groups.Results After treatment, total effective rates of treatment and control groups were 70.59%(36 cases /51 cases) and 50.98%(26 cases /51cases) with significant difference (P<0.05).After treat-ment, the positive expression rates of treatment and control groups were compared : p53 were 39.22%(20 cases /51 cases) and 60.78%(31 cases /51 cases), Ki-67 were 27.45%(14 cases /51 cases) and 47.06%(24 cases /51 cases), MMP-2 were 25.49%(13 cases /51 cases) and 45.10%(23 cases /51 cases), MMP-9 were 27.45%(14 cases /51 cases) and 47.06%(24 cases /51 cases), the differences were statistically significant (all P<0.05). The adverse drug reactions of control group were nausea and vomiting , fever, leukopenia and liver function injury , which in treatment group were nausea and vomiting , leukopenia, fever, gingival hemorrhage , proteinuria and hyperten-sion.The total incidences of adverse drug reactions in the treatment and control groups were 49.02% and 45.10%without significant difference (P>0.05).Conclusion Bevacizumab injection combined with neoadjuvant chemothe-rapy has a definitive clinical efficacy in the treatment of breast cancer , which can significantly reduce the expressions of p53, Ki-67, MMP-2 and MMP-9, without increasing the incidence of adverse drug reactions .
